For research use only. Not for therapeutic Use.
Licostinel (ACEA-1021) is a glycine receptor antagonist (IC50: 59 nM). Licostinel has neuroprotective activity[1][2][3].
| Catalog Number | M101751 |
| CAS Number | 153504-81-5 |
| Synonyms | 6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione |
| Molecular Formula | C8H3Cl2N3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C8H3Cl2N3O4/c9-2-1-3-5(6(4(2)10)13(16)17)12-8(15)7(14)11-3/h1H,(H,11,14)(H,12,15) |
| InChIKey | CHFSOFHQIZKQCR-UHFFFAOYSA-N |
| SMILES | C1=C2C(=C(C(=C1Cl)Cl)[N+](=O)[O-])NC(=O)C(=O)N2 |
| Reference | [1]. Zhou ZL, et al. Synthesis and SAR of novel di- and trisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (Acea 1021) as NMDA/glycine site antagonists. Bioorg Med Chem. 2003 Apr 17;11(8):1769-80. [2]. Albers GW, et al. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke. 1999 Mar;30(3):508-13. [3]. Martin H, et al. Effects of glycine receptor antagonism on spreading depression in the rat. Neurosci Lett. 1994 Oct 24;180(2):285-9. |
